Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 134, Issue 4, 2008, Pages 363-369

  Kumar, Bhavna ^a   Cordell, Kitrina G ^a,b   D'Silva, Nisha ^a,b   Prince, Mark E ^a   Adams, Meredith E ^a   Fisher, Susan G ^c   Wolf, Gregory T ^a   Carey, Thomas E ^a   Bradford, Carol R ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL XL; PROTEIN P53;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MICROARRAY ANALYSIS; ORGAN PRESERVATION; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; BIOLOGICAL MARKERS; CARCINOMA; DISEASE-FREE SURVIVAL; HUMANS; LARYNGEAL NEOPLASMS; LARYNGECTOMY; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 42549096687     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.134.4.363     Document Type: Article

References (32)

1. Bradford CR. Predictive factors in head and neck cancer. Hematol Oncol Clin North Am. 1999;13(4):777-785.
2. Bradford CR, Zhu S, Ogawa H, et al. p53 Mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003;25(8):654-661.
3. Bradford CR, Zhu S, Wolf GT, et al; Department of Veterans Affairs Laryngeal Cancer Study Group. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Otolaryngol Head Neck Surg. 1995;113(4):408-412.
4. Akervall J, Brun E, Dictor M, Wennerberg J. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck: preliminary report. Acta Oncol. 2001;40(4):505-511.
5. Teknos TN, Cox C, Barrios MA, et al. Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. Laryngoscope. 2002;112(5):844-851.
6. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol. 2005;23(24):5560-5567.
7. INK4a expression with p53 alterations in head and neck cancer by tissue microarray analysis. J Pathol. 2007;211(3):314-322.
8. Schimming R, Reusch P, Kuschnierz J, Schmelzeisen R. Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance? J Craniomaxillofac Surg. 2004;32(3):176-181.
9. van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res. 2000;6(6):2138-2145.
10. Villunger A, Michalak EM, Coultas L, et al. p53- And drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302(5647):1036-1038.
11. Oda E, Ohki R, Murasawa H, et al. Noxa: a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288(5468):1053-1058.
12. Temam S, Flahault A, Périé S, et al. p53 Gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2000;18(2):385-394.
13. Reed JC, Miyashita T, Takayama S, et al. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 1996;60(1):23-32.
14. Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395-419.
15. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of Bcl-xL can confer a multidrug resistance phenotype. Blood. 1995;86(5):1903-1910.
16. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol. 2005;17(6):617-625.
17. Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope. 2002;112(4):638-644.
18. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281(5381):1322-1326.
19. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685-1690.
20. Bauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther. 2005;4(7):1096-1104.
21. Bradford CR, Zhu S, Poore J, et al; Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. p53 Mutation as a prognostic marker in advanced laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1997;123(6):605-609.
22. Erber R, Conradt C, Homann N, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene. 1998;16(13):1671-1679.
23. Friedman M, Lim JW, Manders E, et al. Prognostic significance of Bcl-2 and p53 expression in advanced laryngeal squamous cell carcinoma. Head Neck. 2001;23(4):280-285.
24. Pukkila MJ, Kumpulainen EJ, Virtaniemi JA, et al. Nuclear and cytoplasmic p53 expression in pharyngeal squamous cell carcinoma: prognostic implications. Head Neck. 2002;24(8):784-791.
25. Vielba R, Bilbao J, Ispizua A, et al. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope. 2003;113(1):167-172.
26. Bröker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res. 2005;11(9):3155-3162.
27. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol. 2006;24(4):593-598.
28. Kumar B, Cordel KG, Lee JS, et al. EGFR, p16, HPV titer, BLXL, p53, gender, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. In press.
29. Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells [published correction appears in Clin Cancer Res. 2005;11(15):5659]. Clin Cancer Res. 2004;10(22):7757-7763.
30. Wolter KG, Wang SJ, Henson BS, et al. (-)-Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia. 2006;8(3):163-172.
31. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours [letter]. Nature. 2005;435(7042):677-681.
32. Verhaegen M, Bauer JA, Martín de la Vega C, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 2006;66(23):11348-11359.